Annual Results Results Snapshot
Figures in Million
Consolidate Annual Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Net Sales
1,004.99
969.53
816.70
794.62
647.58
602.75
576.69
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
1,004.99
969.53
816.70
794.62
647.58
602.75
576.69
Raw Material Cost
304.71
341.19
301.38
267.91
270.88
255.89
359.36
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
1.33
1.26
1.13
1.07
0.64
0.75
0.93
Selling and Distribution Expenses
298.95
299.97
274.34
295.38
310.33
320.73
494.34
Other Expenses
11.87
11.78
12.89
17.86
18.79
26.64
31.74
Total Expenditure (Excl Depreciation)
723.71
760.19
705.70
742.94
769.79
843.73
1,172.05
Operating Profit (PBDIT) excl Other Income
281.3
209.3
111
51.7
-122.2
-241
-595.4
Other Income
15.10
1.38
15.30
-144.24
-143.33
-69.93
-69.28
Operating Profit (PBDIT)
314.93
226.16
128.63
-107.45
-265.54
-310.91
-664.64
Interest
1.33
1.26
1.13
1.07
0.64
0.75
0.93
Exceptional Items
5.51
0.39
-0.52
-172.09
16.04
1.03
6.88
Gross Profit (PBDT)
700.28
628.34
515.32
526.71
376.70
346.86
217.34
Depreciation
18.54
15.43
2.33
0.00
0.00
0.00
0.00
Profit Before Tax
300.56
209.86
124.64
-280.61
-250.14
-310.63
-658.69
Tax
-28.45
-39.19
-62.05
9.12
8.62
8.20
9.43
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
329.01
249.05
186.69
-289.73
-258.77
-318.83
-668.12
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
329.01
249.05
186.69
-289.73
-258.77
-318.83
-668.12
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
329.01
249.05
186.69
-289.73
-258.77
-318.83
-668.12
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
1,843.37
1,514.36
1,265.31
1,078.62
1,368.35
1,629.28
1,948.46
Earnings per share (EPS)
35.33
26.74
20.05
-31.11
-27.78
-34.23
-76.01
Diluted Earnings per share
35.33
26.74
20.05
-31.11
-27.78
-34.23
-76.01
Operating Profit Margin (Excl OI)
27.99%
21.59%
13.59%
4.63%
-18.87%
-39.98%
-103.24%
Gross Profit Margin
31.75%
23.24%
15.55%
-35.31%
-38.63%
-51.54%
-114.22%
PAT Margin
32.74%
25.69%
22.86%
-36.46%
-39.96%
-52.9%
-115.85%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2026 is 3.66% vs 18.71% in Mar 2025
Consolidate Net Profit
YoY Growth in year ended Mar 2026 is 32.13% vs 33.37% in Mar 2025
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2026 is 33.36% vs 98.41% in Mar 2025
Interest
YoY Growth in year ended Mar 2026 is 0.00% vs 18.18% in Mar 2025
Operating Profit Margin (Excl OI)
YoY Growth in year ended Mar 2026 has improved from Mar 2025
Compare Annual Results Of Immuno-Biological Laboratories Co., Ltd. With
Figures in Million
Consolidate Annual Results
Change(JPY)
Change(%)
Net Sales
1,004.99
32,908.42
-31,903.43
-96.95%
Other Operating Income
0.00
0.00
0.00
Total Operating income
1,004.99
32,908.42
-31,903.43
-96.95%
Raw Material Cost
304.71
27,175.26
-26,870.55
-98.88%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0.00
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
1.33
37.63
-36.30
-96.47%
Selling and Distribution Expenses
298.95
4,969.17
-4,670.22
-93.98%
Other Expenses
11.87
-3.76
15.63
415.69%
Total Expenditure (Excl Depreciation)
723.71
32,144.44
-31,420.73
-97.75%
Operating Profit (PBDIT) excl Other Income
281.28
763.99
-482.71
-63.18%
Other Income
15.10
156.79
-141.69
-90.37%
Operating Profit (PBDIT)
314.93
1,220.67
-905.74
-74.20%
Interest
1.33
37.63
-36.30
-96.47%
Exceptional Items
5.51
-57.68
63.19
109.55%
Gross Profit (PBDT)
700.28
5,733.16
-5,032.88
-87.79%
Depreciation
18.54
299.89
-281.35
-93.82%
Profit Before Tax
300.56
825.46
-524.90
-63.59%
Tax
-28.45
251.16
-279.61
-111.33%
Provisions and contingencies
0
0
0.00
Profit After Tax
329.01
586.63
-257.62
-43.92%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
329.01
586.63
-257.62
-43.92%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
-12.33
12.33
100.00%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
329.01
574.30
-245.29
-42.71%
Equity Capital
0
0
0.00
Face Value
0.00
0.00
0.00
Reserves
1,843.37
7,654.07
-5,810.70
-75.92%
Earnings per share (EPS)
35.33
101.22
-65.89
-65.10%
Diluted Earnings per share
35.33
101.22
-65.89
-65.10%
Operating Profit Margin (Excl OI)
27.99%
2.32%
0.00
25.67%
Gross Profit Margin
31.75%
3.42%
0.00
28.33%
PAT Margin
32.74%
1.78%
0.00
30.96%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 100.50 Million
in Mar 2026Figures in Million
YoY Growth in year ended Mar 2026 is 3.66% vs 18.71% in Mar 2025
Annual - Consolidate Net Profit
Consolidate Net Profit 32.90 Million
in Mar 2026Figures in Million
YoY Growth in year ended Mar 2026 is 32.13% vs 33.37% in Mar 2025
Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 29.98 Million
in Mar 2026Figures in Million
YoY Growth in year ended Mar 2026 is 33.36% vs 98.41% in Mar 2025
Annual - Interest
Interest 0.13 Million
in Mar 2026Figures in Million
YoY Growth in year ended Mar 2026 is 0.00% vs 18.18% in Mar 2025
Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 27.99%
in Mar 2026Figures in %
YoY Growth in year ended Mar 2026 has improved from Mar 2025
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
